Sponsored Links
| SciClone Announces Enrollment Completion In Phase 2 Oral Mucositis Trial Of SCV-07 |
 |
 |
 |
| Medical News - Ear, Nose and Throat | |||
|
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) announced that patient enrollment is complete ahead of schedule for its phase 2 trial of SCV-07 -- a small molecule synthetic peptide with immunomodulating properties -- for the treatment of severe oral mucositis (OM) in patients with head and neck cancer... Read more: Ear, Nose and Throat News From Medical News Today
|